02096.HK
Simcere Pharmaceutical Group Limited
HKSE · Healthcare · Biotechnology · CN
HKD 10.14
−2.31%Oct 27, 2026, 09:46 UTC
Simcere Pharmaceutical Group Ltd. repurchased 1.042 million shares at HK$10.15–HK$10.41 per share for approximately HK$10.751 million.
Source:Oct 14, 2026, 00:55 UTC
Simcere Pharmaceutical Group Ltd. repurchased 1.428 million shares for approximately HK$15.3431 million at HK$10.5438–10.82 per share.
Source:Oct 9, 2026, 10:18 UTC
Simcere Pharmaceutical Group Ltd. repurchased 1.598 million shares for approximately HK$17.3699 million at HK$10.66–11.003 per share.
Source:Aug 31, 2026, 23:17 UTC
China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.
Aug 21, 2026, 07:27 UTC
Simcere Pharmaceutical announced that Zhou Yunshu stepped down as CEO and was appointed President, while founder Ren Jinsheng resumed the role of CEO, effective August 20, 2026.
Source:Aug 20, 2026, 03:05 UTC
Simcere Pharmaceutical announced a strategic partnership with Ruiyang (Shandong) Biopharmaceutical to obtain exclusive commercialization rights in Greater China for the novel biologic drug Kuleweibai injection.